| scholarly article | Q13442814 |
| P50 | author | Robert K Hills | Q37830377 |
| Tatjana Stankovic | Q63808874 | ||
| P2093 | author name string | Chris Pepper | |
| Chris Fegan | |||
| Guy Pratt | |||
| Paul Brennan | |||
| Rachel Ward | |||
| Louise Hiller | |||
| Jane Starczynski | |||
| Belinda Austen | |||
| Saman Hewamana | |||
| Thet Thet Lin | |||
| Laura Hooper | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| lymphocyte | Q715347 | ||
| chronic lymphocytic leukemia | Q1088156 | ||
| P304 | page(s) | 3807-3817 | |
| P577 | publication date | 2008-07-03 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers | |
| P478 | volume | 112 |
| Q38457498 | A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine |
| Q37235687 | A role for IRF4 in the development of CLL. |
| Q63364698 | AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival |
| Q37039117 | AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance |
| Q37866334 | Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets |
| Q37168329 | Accelerated development of chronic lymphocytic leukemia in New Zealand Black mice expressing a low level of interferon regulatory factor 4. |
| Q36111609 | Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1 |
| Q39807151 | Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition |
| Q35266213 | An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. |
| Q38187815 | Apoptosis inducers in chronic lymphocytic leukemia |
| Q37694914 | Association of Bax Expression and Bcl2/Bax Ratio with Clinical and Molecular Prognostic Markers in Chronic Lymphocytic Leukemia |
| Q36907112 | BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. |
| Q36866417 | BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors |
| Q42773124 | Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells |
| Q100455045 | Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients |
| Q36483749 | Broad targeting of resistance to apoptosis in cancer. |
| Q39560150 | CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. |
| Q37902948 | Chronic lymphocytic leukemia: an update on biology and treatment. |
| Q47105863 | Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70. |
| Q38103591 | Death receptors as targets in cancer |
| Q99579609 | Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia |
| Q37997623 | Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia |
| Q34285688 | Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia |
| Q39065374 | Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). |
| Q34369809 | Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance |
| Q36688994 | Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. |
| Q64086520 | Evaluation of gilteritinib in combination with chemotherapy in preclinical models of acute myeloid leukemia |
| Q34056568 | Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia |
| Q36254232 | Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia |
| Q39434928 | Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. |
| Q24633394 | Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia |
| Q91580906 | Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells |
| Q34568840 | Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia |
| Q37317633 | Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. |
| Q37725415 | Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells |
| Q34231324 | Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia |
| Q50929308 | In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent. |
| Q64076534 | Increased expression predicts poor prognosis and disease recurrence in acute myeloid leukemia |
| Q37778876 | Inflammation and survival pathways: chronic lymphocytic leukemia as a model system |
| Q34122323 | Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells |
| Q42446777 | Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells |
| Q39663702 | Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF-κB Activation andDe novoGene Transcription |
| Q26781895 | Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia |
| Q35143479 | LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia |
| Q36349985 | Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) |
| Q37251592 | Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells |
| Q40338396 | Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. |
| Q37066223 | Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab |
| Q33882849 | Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. |
| Q37187536 | Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia |
| Q38787624 | Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1. |
| Q42272463 | Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells. |
| Q51712946 | Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis. |
| Q54519290 | N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity. |
| Q34202277 | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio |
| Q37690750 | NF-kappaB as a therapeutic target in chronic lymphocytic leukemia |
| Q55668973 | NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. |
| Q38190095 | New treatment options for chronic lymphocytic leukemia. |
| Q36140862 | Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL. |
| Q42144156 | Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features |
| Q45801633 | Over-expression of Mcl-1 impairs the ability of ATRA to induce growth arrest and differentiation in acute promyelocytic leukemia cells |
| Q34541989 | Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers |
| Q37306304 | Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia |
| Q39170184 | Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B |
| Q55280895 | Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia. |
| Q26771601 | Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? |
| Q38755091 | Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia |
| Q35089766 | Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8. |
| Q34255118 | Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk |
| Q38268442 | Protein kinase C in cellular transformation: a valid target for therapy? |
| Q35125652 | Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation |
| Q37978344 | RNA-based markers as prognostic factors in chronic lymphocytic leukemia |
| Q38891225 | ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia |
| Q43243964 | Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. |
| Q26781203 | Regulation of Bim in Health and Disease |
| Q35022490 | Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q35483640 | SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target |
| Q42752579 | Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. |
| Q54704847 | Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. |
| Q34508337 | Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. |
| Q27675842 | Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities |
| Q101165825 | Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance |
| Q90047057 | Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q35011166 | The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells |
| Q92259261 | The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors |
| Q38826234 | The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. |
| Q38597740 | The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells |
| Q28075683 | The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia |
| Q35083049 | The essential role of evasion from cell death in cancer |
| Q37564440 | The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells |
| Q37187540 | The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo |
| Q26865760 | The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy |
| Q42924738 | The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells |
| Q28075504 | The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia |
| Q30395427 | The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. |
| Q45937702 | The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. |
| Q38442515 | Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies |
| Q28484291 | Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer |
| Q39283981 | Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma |
| Q54584717 | Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. |
| Q38126317 | Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis |
| Q35550068 | Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia |
| Q34382986 | VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia |
| Q49436424 | ZGDHu-1 for cancer therapy |
| Q36785683 | miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. |
| Q36247617 | miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. |
| Q46067297 | γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. |
Search more.